Page last updated: 2024-09-05

deferasirox and Stroke

deferasirox has been researched along with Stroke in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA1
Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC1
Rempe, DA; Zhao, Y1
Alvarez, O; Cohen, AR; Garro, J; Kwiatkowski, JL; Lane, P; Mortier, N; Mueller, B; Nagasubramanian, R; Sarnaik, S; Schultz, W; Thompson, A; Ware, RE; Woods, GM; Yovetich, N1

Trials

3 trial(s) available for deferasirox and Stroke

ArticleYear
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult

2013
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
    American journal of hematology, 2015, Volume: 90, Issue:9

    Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial

2015
Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    American journal of hematology, 2012, Volume: 87, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Benzoates; Chelation Therapy; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult

2012

Other Studies

1 other study(ies) available for deferasirox and Stroke

ArticleYear
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2011, Volume: 31, Issue:6

    Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles

2011